RESUMO
BACKGROUND: Devolution of healthcare services in Kenya resulted in a large number of newly recruited tuberculosis (TB) coordinators. We describe a unique collaboration between a national tuberculosis program (NTP), a local, and an international non-governmental organization to build human resource capacity in TB care and prevention. METHODS: From 2016 to 2021, the Kenya Division of National Tuberculosis, Leprosy and Lung Disease Program, Centre for Health Solutions-Kenya, and the International Union Against Tuberculosis and Lung Disease developed and conducted a series of 7-day training courses. A key focus of training was the introduction of TBData4Action, an approach involving the local use of routinely available data to strengthen decision-making and support supervision. RESULTS: Implementation outcomes included training 331 (96%) coordinators out of 344, representing all 47 counties, 37 national officers and 21 other stakeholders using the country-tailored curriculum, including hands-on group work by county teams and field practicals. Thirty-five national facilitators were identified and mentored as local faculty. Training costs were reduced by 75% compared with international alternatives. CONCLUSION: The collaboration resulted in the training of the majority of the coordinators in a standardized approach to TB care. A sustainable approach to capacity building in local data use was found feasible; the model could be adapted by other NTPs.
CONTEXTE: La décentralisation des services de santé au Kenya a conduit au recrutement d'un grand nombre de nouveaux coordinateurs TB. Nous décrivons une collaboration unique entre un programme national de lutte contre la TB (NTP), une organisation non gouvernementale locale et une organisation non gouvernementale internationale visant à renforcer les capacités humaines en matière de prévention et de soins de la TB. MÉTHODES: De 2016 à 2021, la division kényane du programme national de lutte contre la tuberculose, la lèpre et les maladies respiratoires, le Centre for Health Solutions-Kenya et l'Union internationale contre la tuberculose et les maladies respiratoires ont développé et dispensé une série de formations en 7 jours. La formation mettait l'accent sur l'introduction de l'approche TBData4Action, qui promeut une utilisation locale des données disponibles en routine afin de renforcer la prise de décision et d'épauler les activités de supervision. RÉSULTATS: Les résultats de la mise en place de cette formation comprenaient la formation de 331 (96%) coordinateurs sur 344, représentant l'ensemble des 47 pays, 37 administrateurs nationaux et 21 autres acteurs formés à l'aide du programme adapté aux besoins du pays concerné (dont travail de groupe pratique par les équipes nationales et travaux pratiques sur le terrain). Trente-cinq facilitateurs nationaux ont été identifiés et formés comme enseignants locaux. Les coûts de la formation ont été réduits de 75% par rapport aux alternatives internationales. CONCLUSION: La collaboration a permis de former la majorité des coordinateurs à l'aide d'une approche standardisée de soins de la TB. Une approche durable de renforcement des capacités en matière d'utilisation des données locales s'est avérée réalisable. Ce modèle peut être adapté à d'autres NTP.
RESUMO
SETTING: Despite Uganda's efforts to improve tuberculosis and human immunodeficiency virus (TB-HIV) collaborative services, implementation remains low and operational barriers have not been systematically identified and documented. OBJECTIVE: To assess barriers to implementation of TB-HIV collaborative services in five districts in Uganda. DESIGN: In this qualitative study, focus groups and key informant and in-depth interviews were conducted for patients (HIV, TB), health providers and community members. TB registers were also assessed for data on use of TB-HIV collaborative services. RESULTS: Of 333 adult TB patients registered between July and September 2006, 185 (56%) were tested for HIV, of whom 134 were HIV-co-infected. Of these, 52% were on cotrimoxazole preventive therapy (CPT), 12% were on antiretroviral therapy (ART) and CPT, while 36% had not received any HIV service. Health system barriers identified included poor TB-HIV planning, coordination and leadership, inadequate dissemination of policy, inadequate provider knowledge, limited TB-HIV interclinic referral, poor service integration and recording, logistical shortages, high costs of services and provider shortages amidst high patient loads. CONCLUSION: Implementation and utilisation of collaborative TB-HIV services remains suboptimal. The barriers identified highlight the need for TB and HIV programmes to support districts to plan, coordinate and invest resources in TB-HIV collaborative services, especially in policy dissemination, training health providers, integration of TB-HIV services, logistical management and monitoring.
Assuntos
Serviços de Saúde Comunitária/organização & administração , Tuberculose/terapia , Adulto , Grupos Focais , Humanos , UgandaRESUMO
Isoniazid preventive therapy (IPT) is recognised as an important component of collaborative tuberculosis (TB) and human immunodeficiency virus (HIV) activities to reduce the burden of TB in people living with HIV (PLHIV). However, there has been little in the way of IPT implementation at country level. This failure has resulted in a recent call to arms under the banner title of the 'Three I's' (infection control to prevent nosocomial transmission of TB in health care settings, intensified TB case finding and IPT). In this paper, we review the background of IPT. We then discuss the important challenges of IPT in PLHIV, namely responsibility and accountability for the implementation, identification of latent TB infection, exclusion of active TB and prevention of isoniazid resistance, length of treatment and duration of protective efficacy. We also highlight several research questions that currently remain unanswered. We finally offer practical suggestions about how to scale up IPT in the field, including the need to integrate IPT into a package of care for PLHIV, the setting up of operational projects with the philosophy of 'learning while doing', the development of flow charts for eligibility for IPT, the development and implementation of care prior to antiretroviral treatment, and finally issues around procurement, distribution, monitoring and evaluation. We support the implementation of IPT, but only if it is done in a safe and structured way. There is a definite risk that 'sloppy' IPT will be inefficient and, worse, could lead to the development of multidrug-resistant TB, and this must be avoided at all costs.
Assuntos
Antituberculosos/uso terapêutico , Infecções por HIV/epidemiologia , Isoniazida/uso terapêutico , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Comorbidade , Resistência Microbiana a Medicamentos , Saúde Global , Humanos , Saúde PúblicaRESUMO
Assuntos
Atenção à Saúde/organização & administração , Transtornos Mentais/terapia , Serviços de Saúde Mental/organização & administração , Tuberculose/terapia , Estudos Transversais , Atenção à Saúde/estatística & dados numéricos , Saúde Global , Infecções por HIV/epidemiologia , Humanos , Incidência , Programas de Rastreamento/estatística & dados numéricos , Serviços de Saúde Mental/estatística & dados numéricos , Guias de Prática Clínica como Assunto , Estigma Social , Transtornos Relacionados ao Uso de Substâncias/terapia , Inquéritos e Questionários , Tuberculose/psicologia , Tuberculose Resistente a Múltiplos Medicamentos/psicologia , Tuberculose Resistente a Múltiplos Medicamentos/terapiaRESUMO
Assuntos
Antituberculosos/administração & dosagem , Qualidade da Assistência à Saúde , Tuberculose/terapia , Cobertura Universal do Seguro de Saúde , Estudos de Coortes , Estudos de Viabilidade , Infecções por HIV/epidemiologia , Humanos , Projetos Piloto , Estudos Retrospectivos , Tuberculose/diagnóstico , Tuberculose/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/diagnóstico , Tuberculose Resistente a Múltiplos Medicamentos/epidemiologia , Tuberculose Resistente a Múltiplos Medicamentos/terapia , Tuberculose Pulmonar/diagnóstico , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/terapia , ZimbábueRESUMO
SETTING: A resource-limited urban setting in Zimbabwe with a high burden of tuberculosis (TB) and human immunodeficiency virus (HIV). OBJECTIVES: To determine the feasibility and yield of diabetes mellitus (DM) screening among TB patients in primary health care facilities. DESIGN: A descriptive study. RESULTS: Of the 1617 TB patients registered at 10 pilot facilities, close to two thirds (60%) were male and 798 (49%) were bacteriologically confirmed. The median age was 37 years; two thirds (67%) were co-infected with HIV. A total of 1305 (89%) were screened for DM, and 111 (8.5%, 95% CI 7.0-10.2) were newly diagnosed with DM. Low TB notifying sites were more likely than high TB notifying sites to screen patients using random blood glucose (RBG) (83% vs. 79%; P < 0.04). Screening increased gradually per quarter over the study period. There were, however, notable losses along the screening cascade, the reasons for which will need to be explored in future studies. CONCLUSION: The study findings indicate the feasibility of DM screening among TB patients, with considerable yield of persons newly diagnosed with DM. Scaling up of this intervention will need to address the observed losses along the screening cascade.
RESUMO
The international community has committed to end the tuberculosis (TB) epidemic by 2030. To facilitate the meeting of the global incidence and mortality indicators set by the World Health Organization's End TB Strategy, the Stop TB Partnership launched the three 90-(90)-90 diagnostic and treatment targets in 2014. In this paper, we argue that a 'fourth 90'-Ensuring that 90% of all people successfully completing treatment for TB can have a good health-related quality of life'-should be considered. Many individuals who successfully complete anti-TB treatment are burdened with lifelong comorbidities-human immunodeficiency virus (HIV) and diabetes mellitus, obstructive and restrictive lung disease, involving lung destruction, cavitation, fibrosis and bronchiectasis, that either pre-existed or developed as a result of TB (e.g., chronic pulmonary aspergillosis), permanent disabilities such as hearing loss resulting from second-line anti-TB drugs, and mental health disorders. These need to be identified during TB treatment and appropriate care and support provided after anti-TB treatment is successfully completed. A 'fourth 90' has also been proposed for the UNAIDS 90-90-90 targets similar in scope to what is being suggested here for TB. Adoption by both HIV and TB control programmes would highlight the current focus on integrated person- and family-centred services.
Assuntos
Promoção da Saúde , Tuberculose Pulmonar/epidemiologia , Saúde Global , Humanos , Tuberculose Pulmonar/prevenção & controleRESUMO
People living with the human immunodeficiency virus (HIV) (PLHIV) are at high risk for tuberculosis (TB), and TB is a major cause of death in PLHIV. Preventing TB in PLHIV is therefore a key priority. Early initiation of antiretroviral therapy (ART) in asymptomatic PLHIV has a potent TB preventive effect, with even more benefits in those with advanced immunodeficiency. Applying the most recent World Health Organization recommendations that all PLHIV initiate ART regardless of clinical stage or CD4 cell count could provide a considerable TB preventive benefit at the population level in high HIV prevalence settings. Preventive therapy can treat tuberculous infection and prevent new infections during the course of treatment. It is now established that isoniazid preventive therapy (IPT) combined with ART among PLHIV significantly reduces the risk of TB and mortality compared with ART alone, and therefore has huge potential benefits for millions of sufferers. However, despite the evidence, this intervention is not implemented in most low-income countries with high burdens of HIV-associated TB. HIV and TB programme commitment, integration of services, appropriate screening procedures for excluding active TB, reliable drug supplies, patient-centred support to ensure adherence and well-organised follow-up and monitoring that includes drug safety are needed for successful implementation of IPT, and these features would also be needed for future shorter preventive regimens. A holistic approach to TB prevention in PLHIV should also include other important preventive measures, such as the detection and treatment of active TB, particularly among contacts of PLHIV, and control measures for tuberculous infection in health facilities, the homes of index patients and congregate settings.
Assuntos
Fármacos Anti-HIV/administração & dosagem , Antituberculosos/administração & dosagem , Infecções por HIV/epidemiologia , Tuberculose/prevenção & controle , Contagem de Linfócito CD4 , Países em Desenvolvimento , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Humanos , Isoniazida/administração & dosagem , Pobreza , Tuberculose/epidemiologiaRESUMO
Integrating the management and care of communicable diseases, such as tuberculosis (TB) and human immunodeficiency virus/acquired immune-deficiency syndrome (HIV/AIDS), and non-communicable diseases, particularly diabetes mellitus (DM), may help to achieve the ambitious health-related targets of the Sustainable Development Goals (SDG 3.3 and 3.4) by 2030. There are five important reasons to integrate. First, we need to integrate to prevent disease. In sub-Saharan Africa, in particular, HIV infection is the main driver of the TB epidemic, and antiretroviral therapy combined with isoniazid preventive therapy (IPT) can reduce TB case notification rates. In Asia, DM is another important driver of the TB epidemic, and preventing or controlling DM can reduce the risk of TB. Second, we need to integrate to diagnose cases. Between a third to a half of those living with HIV, TB or DM do not know they have the disease, and bi-directional screening, whereby TB patients are screened for HIV and DM or people living with HIV and DM are screened for TB, can help to identify these 'missing cases'. Third, we need to integrate to better treat and manage patients who have a combination of two or more of these diseases, so that treatment success and retention on treatment can be optimised. Fourth, we should integrate to ensure better infection control practices for both TB and HIV infection in health facilities and congregate settings, such as prisons. Finally, we should integrate and learn how to monitor, record and report, particularly in relation to the cascade of events implicit in the HIV/AIDS and TB 90-90-90 targets.
Assuntos
Prestação Integrada de Cuidados de Saúde/organização & administração , Prestação Integrada de Cuidados de Saúde/normas , Diabetes Mellitus/prevenção & controle , Infecções por HIV/epidemiologia , Tuberculose/prevenção & controle , Antirretrovirais/uso terapêutico , Antituberculosos/uso terapêutico , Pesquisa Biomédica , Diabetes Mellitus/diagnóstico , Infecções por HIV/tratamento farmacológico , Humanos , Isoniazida/uso terapêutico , Programas de Rastreamento/organização & administração , Guias de Prática Clínica como Assunto , Tuberculose/diagnóstico , Organização Mundial da SaúdeRESUMO
Setting: Three projects of the Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB. Objectives: To assess unfavourable treatment outcomes (UTOs), including failure, died, loss to follow-up (LTFU), transferred out and unknown outcome, and to identify risk factors associated with UTOs. Design: This was a cross-sectional study using routine programme data. Results: Of 30 277 new smear-positive tuberculosis (TB) patients, 4261 (14.1%) had UTOs: 2048 (6.8%) LTFU, 1418 (4.7%) transferred out, 390 (1.3%) died, 340 (1.1%) failed and 65 (0.2%) had an unknown outcome. Risk factors for LTFU (including LTFU, transfer out and unknown outcome) were residing in Anhui, age > 55 years, service delay > 10 days, patient delay < 30 days, directly observed treatment (DOT) provided by a family member or others and unknown DOT provider. The outcome of 'died' was associated with residing in Shaanxi, age > 55 years, male sex, patient delay > 30 days and unknown DOT provider. 'Failed' was associated with having unlimited access to health services, patient delay of >30 days and unknown DOT provider. Conclusion: This study highlights the predominance of lost patients among UTOs. Patients with family members or other non-medical DOT providers or unknown DOT providers had a high risk of a UTO. There is an urgent need to address these service-related factors.
Contexte : Trois projets du Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB (FIDELIS).Objectifs : Evaluer les résultats défavorables du traitement (UTO) incluant l'échec, le décès, les pertes de vue, les transferts et les résultats inconnus, et identifier les facteurs de risque associés aux UTO.Schéma : Une étude transversale basée sur des données de routine du programme.Résultats : De 30 277 nouveaux patients TB à frottis positif, 4261 (14,1%) ont eu un UTO : perdus de vue (2048 ; 6,8%), transférés (1418 ; 4,7%), décédés (390 ; 1,3%), en échec (340 ; 1,1%) ou inconnus (65 ; 0,2%). Les facteurs de risque de perte d'un patient (incluant les patients perdus de vue, transférés et inconnus) ont été le fait de vivre à Anhui, l'âge > 55 ans, un délai du service > 10 jours, un retard du patient < 30 jours et le traitement directement observé (DOT) fourni par un membre de la famille ou d'autres personnes ou un prestataire de DOT inconnu. Le résultat « décès ¼ a été associé avec le fait de vivre à Shaanxi, l'âge > 55 ans, le sexe masculin, un retard du patient > 30 jours et un prestataire de DOT inconnu. Un « échec ¼ a été associé avec un accès non limité aux services de santé, un retard du patient > 30 jours et un prestataire de DOT inconnu.Conclusion : L'étude a mis en lumière la prédominance de pertes de vue parmi les UTO. Les patients ayant comme prestataire de DOT un membre de la famille ou un autre prestataire non médical ou inconnu ont eu un risque élevé d'UTO. Il y a un besoin urgent d'aborder ces facteurs liés au service.
Marco de referencia: Tres proyectos del Fondo de Estrategias Innovadoras de Ampliación de DOTS mediante Iniciativas Locales para Detener la Tuberculosis (FIDELIS).Objetivos: Evaluar los desenlaces terapéuticos desfavorables (UTO) que incluyen el fracaso terapéutico, la muerte, la pérdida durante el seguimiento, la transferencia a otro centro y el desenlace desconocido y definir los factores de riesgo que se asocian con estos resultados.Método: Un estudio transversal a partir de los datos corrientes del programa.Resultados: Se incluyeron en el estudio 30 277 casos nuevos de tuberculosis (TB) con baciloscopia positiva. De estos pacientes, 4261 tuvieron UTO (14,1%), a saber: perdidos durante el seguimiento (2048; 6,8%), transferidos a otro centro (1418; 4,7%), fallecidos (390; 1,3%), fracasos (340; 1,1%) o desenlaces desconocidos (65; 0,2%). En Anhui, los factores de riesgo de pérdida durante el seguimiento (incluidas las pérdidas, las transferencias a otro centro y los desenlaces desconocidos) fueron la edad > 55 años, un retraso dependiente del servicio > 10 días, un retraso dependiente del paciente < 30 días y el tratamiento bajo observación directa (DOT) suministrado por miembros de la familia u otras personas y un dispensador de DOT desconocido. En Shaanxi, el desenlace 'fallecido' se asoció con la edad > 55 años, el sexo masculino, un retraso dependiente del paciente > 30 días y un dispensador de DOT desconocido. El 'fracaso' se asoció con el hecho de no pertenecer a la categoría de acceso limitado a los servicios de salud, el retraso dependiente del paciente > 30 días y un dispensador de DOT desconocido.Conclusión: El estudio puso de manifiesto el predominio de la pérdida durante el seguimiento en los desenlaces desfavorables del tratamiento antituberculoso. Los pacientes que recibían el DOT por parte de un miembro de la familia o de otra persona diferente a un profesional de salud o cuyo dispensador de DOT se desconocía presentaron un alto riesgo de UTO. Es urgente abordar estos factores que dependen de los servicios de salud.
RESUMO
Because of the increasing availability of antiretroviral (ARV) agents for HIV in low-income countries, many clinicians now need training on their use. This is especially true for clinicians caring for individuals with tuberculosis (TB), given its close relationship with HIV/AIDS. This article summarizes the key decisions facing clinicians who manage HIV-infected persons, with particular reference to issues regarding those dually infected with TB. Health care provider-initiated diagnostic testing using rapid HIV tests should be offered to all individuals with symptoms and signs suggesting HIV infection, including all persons with TB. Issues to be included in pre- and post-test counseling sessions are discussed. HIV-infected patients should be evaluated to determine clinical staging of HIV; certain laboratory examinations should ideally be performed to assess the degree of immunosuppression and to aid decisions about when best to start ARV therapy and preventive therapies. The recommended ARV regimens and guidance on proposed patient follow-up are presented. Good adherence to ARVs is required and factors that induce and reinforce compliance are suggested. The treatment of TB is a high priority, and follows the same principles whether the patient is HIV-infected or not. Suggestions are made about ARV use in patients with TB. A standardized and complementary information system should be developed to monitor management of HIV-TB patients and performance of joint TB and HIV care efforts. By diagnosing and managing additional HIV cases detected through the portal of the TB control programme, clinicians will contribute to diminishing the burden of HIV, and thus, TB.
Assuntos
Antirretrovirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , Tuberculose/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/sangue , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/epidemiologia , Antibióticos Antituberculose/uso terapêutico , Comorbidade , Infecções por HIV/classificação , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Humanos , Cooperação do Paciente , Áreas de Pobreza , Inibidores da Transcriptase Reversa/uso terapêutico , Rifampina/uso terapêutico , Tuberculose/diagnósticoRESUMO
SETTING: Emakhandeni Clinic provides decentralised and integrated tuberculosis (TB) and human immunodeficiency virus (HIV) care in Bulawayo, Zimbabwe. OBJECTIVES: To compare HIV care for presumptive TB patients with and without TB registered in 2013. DESIGN: Retrospective cohort study using routine programme data. RESULTS: Of 422 registered presumptive TB patients, 26% were already known to be HIV-positive. Among the remaining 315 patients, 255 (81%) were tested for HIV, of whom 190 (75%) tested HIV-positive. Of these, 26% were diagnosed with TB and 71% without TB (3% had no TB result recorded). For the 134 patients without TB, antiretroviral treatment (ART) eligibility data were recorded for 42 (31%); 95% of these were ART eligible. Initiation of cotrimoxazole preventive therapy (CPT) and ART was recorded for respectively 88% and 90% of HIV-positive patients with TB compared with respectively 40% and 38% of HIV-positive patients without TB (P < 0.001). CONCLUSION: Presumptive TB patients without TB had a high HIV positivity rate and, for those with available data, most were ART eligible. Unlike HIV-positive patients diagnosed with TB, CPT and ART uptake for these patients was poor. A 'test and treat' approach and better service linkages could be life-saving for these patients, especially in southern Africa, where there are high burdens of HIV and TB.
Contexte : Le centre de santé Emakhandeni, qui offre une prise en charge de la tuberculose (TB) et du virus de l'immunodéficience humaine (VIH) décentralisée et intégrée à Bulawayo, Zimbabwe.Objectifs : Comparer la prise en charge du VIH pour les patients présumés tuberculeux, avec et sans TB, enregistrés en 2013.Schéma : Etude rétrospective de cohorte basée sur les données de routine du programme.Résultats: Sur 422 patients présumés tuberculeux enregistrés, 26% étaient connus comme VIH positifs. Parmi les 315 patients restants, 255 (81%) ont eu un test VIH, dont 190 (75%) se sont avérés positifs. Parmi eux, 26% ont eu un diagnostic de TB et 71% n'ont pas été confirmés tuberculeux (les 3% restants n'ont eu aucun résultat de TB enregistré). Pour les 134 patients sans TB, les données d'éligibilité au traitement antirétroviral (ART) ont été notées chez 42 (31%) patients et 95% ont été éligibles à l'ART. La mise en Åuvre du traitement préventif par cotrimoxazole (CPT) et l'ART a été notée pour respectivement 88% et 90% des patients VIH positifs avec TB, comparés à respectivement 40% et 38% des patients VIH positifs sans TB (P < 0,001).Conclusion : Les patients présumés TB mais non confirmés avaient un taux élevé de positivité au VIH et pour ceux dont les données étaient disponibles, la majorité était éligible à l'ART. Par contre, pour les patients VIH positifs sans une TB confirmée, le taux de mise en Åuvre du traitement préventif par CPT et de l'ART a été médiocre. Une approche « tester et traiter ¼ et de meilleurs liens entre les services pourraient sauver la vie de ces patients, surtout en Afrique australe où les taux de VIH et de TB sont très élevés.
Marco de referencia: El consultorio Emakhandeni ofrece atención descentralizada e integrada de la tuberculosis (TB) y la infección por el virus de la inmunodeficiencia humana (VIH) en Bulawayo, Zimbabue.Objetivo: Comparar el servicio de atención de la infección por el VIH en los pacientes registrados con presunción clínica de TB cuyo diagnóstico se confirmó o se infirmó en el 2013.Método: Fue este un estudio retrospectivo de cohortes a partir de los datos corrientes del programa.Resultados: De los 422 pacientes registrados con presunción clínica de TB, el 26% contaba ya con una serología positiva frente al VIH. De los 315 pacientes restantes, en 255 se practicó la serología (81%) y 190 obtuvieron un resultado positivo (75%). De estos pacientes se confirmó el diagnóstico de TB en el 26% y se infirmó en el 71% (en el 3% no se registró ningún resultado sobre la TB). De los 134 pacientes sin TB, se consignaron datos sobre los criterios de inclusión en el tratamiento antirretrovírico (ART) en 42 casos (31%) y el 95% cumplía con estos criterios. En los pacientes seropositivos frente al VIH con TB se registró el comienzo del tratamiento preventivo con cotrimoxazol (CPT) en el 88% y del ART en el 90%, en comparación con el 40% y el 38%, respectivamente, en los pacientes seropositivos sin diagnóstico de TB (P < 0,001).Conclusión: Los pacientes con presunción clínica de TB en quienes se infirmó el diagnóstico presentaron una alta tasa de seropositividad frente al VIH y en los pacientes con datos registrados, la mayoría cumplía con los criterios de iniciación del ART. En estos pacientes la aceptación del CPT y el ART fue baja, a diferencia de los pacientes seropositivos con diagnóstico de TB. Una estrategia de 'prueba diagnóstica y tratamiento' y una mayor vinculación de los servicios podrían contribuir a salvar vidas en este grupo de pacientes, sobre todo en el sur de África, donde existen altas tasas de morbilidad por la infección por el VIH y la TB.